FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564262017> ?p ?o ?g. }

• W2564262017 endingPage "676" @default.
• W2564262017 startingPage "671" @default.
• W2564262017 abstract "Purpose: This study compared the effects of 3 antivascular endothelial growth factor (VEGF) agents (bevacizumab, ranibizumab, and aflibercept) on corneal epithelial cell viability and wound healing using human corneal epithelial cells (HCECs). Methods: To determine the cytotoxic effects of anti-VEGF agents on HCECs, HCEC viability was determined at various concentrations of these agents. An in vitro migration assay was used to investigate the migration of HCECs treated with 3 anti-VEGF agents. The protein level of extracellular signal-regulated kinase was used to evaluate the effect of anti-VEGF treatment on cell proliferation. The protein levels of p38 mitogen-activated protein kinase (MAPK) were analyzed by Western blotting to investigate cell migration. Results: After 24 or 48 h of exposure, aflibercept treatment showed no apparent effect on cell viability; however, bevacizumab and ranibizumab treatment decreased cell viability at high concentrations (1 and 2 mg/mL). A migration assay showed that HCEC migration was different among the 3 anti-VEGF treatment groups. Bevacizumab significantly delayed HCEC migration. Western blotting showed that bevacizumab treatment decreased the expression levels of phosphorylated p38 MAPK. Conclusions: Bevacizumab, the most widely used and investigated anti-VEGF agent, decreased epithelial cell migration and viability. Anti-VEGF agents other than bevacizumab might therefore be better for treating corneal neovascularization complicated with epithelial defects." @default.
• W2564262017 created "2017-01-06" @default.
• W2564262017 creator A5010448477 @default.
• W2564262017 creator A5027504801 @default.
• W2564262017 creator A5031382858 @default.
• W2564262017 date "2016-12-01" @default.
• W2564262017 modified "2023-09-25" @default.
• W2564262017 title "Differential Effects of Bevacizumab, Ranibizumab, and Aflibercept on the Viability and Wound Healing of Corneal Epithelial Cells" @default.
• W2564262017 cites W1537855055 @default.
• W2564262017 cites W1916979106 @default.
• W2564262017 cites W1963898471 @default.
• W2564262017 cites W1967990316 @default.
• W2564262017 cites W1968366019 @default.
• W2564262017 cites W1976918086 @default.
• W2564262017 cites W1981934908 @default.
• W2564262017 cites W1993609386 @default.
• W2564262017 cites W1996802631 @default.
• W2564262017 cites W2012796251 @default.
• W2564262017 cites W2028528029 @default.
• W2564262017 cites W2037473199 @default.
• W2564262017 cites W2041792137 @default.
• W2564262017 cites W2074301535 @default.
• W2564262017 cites W2100027888 @default.
• W2564262017 cites W2114237026 @default.
• W2564262017 cites W2119617160 @default.
• W2564262017 cites W2124415048 @default.
• W2564262017 cites W2126785007 @default.
• W2564262017 cites W2324541703 @default.
• W2564262017 cites W2344129365 @default.
• W2564262017 cites W829349618 @default.
• W2564262017 doi "https://doi.org/10.1089/jop.2016.0094" @default.
• W2564262017 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5165662" @default.
• W2564262017 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27827554" @default.
• W2564262017 hasPublicationYear "2016" @default.
• W2564262017 type Work @default.
• W2564262017 sameAs 2564262017 @default.
• W2564262017 citedByCount "6" @default.
• W2564262017 countsByYear W25642620172017 @default.
• W2564262017 countsByYear W25642620172020 @default.
• W2564262017 countsByYear W25642620172021 @default.
• W2564262017 crossrefType "journal-article" @default.
• W2564262017 hasAuthorship W2564262017A5010448477 @default.
• W2564262017 hasAuthorship W2564262017A5027504801 @default.
• W2564262017 hasAuthorship W2564262017A5031382858 @default.
• W2564262017 hasBestOaLocation W25642620172 @default.
• W2564262017 hasConcept C104317684 @default.
• W2564262017 hasConcept C126322002 @default.
• W2564262017 hasConcept C137738243 @default.
• W2564262017 hasConcept C1491633281 @default.
• W2564262017 hasConcept C167734588 @default.
• W2564262017 hasConcept C184235292 @default.
• W2564262017 hasConcept C185592680 @default.
• W2564262017 hasConcept C203014093 @default.
• W2564262017 hasConcept C2776694085 @default.
• W2564262017 hasConcept C2777025900 @default.
• W2564262017 hasConcept C2777802072 @default.
• W2564262017 hasConcept C2778749236 @default.
• W2564262017 hasConcept C2780269544 @default.
• W2564262017 hasConcept C2781100027 @default.
• W2564262017 hasConcept C502942594 @default.
• W2564262017 hasConcept C53227056 @default.
• W2564262017 hasConcept C55493867 @default.
• W2564262017 hasConcept C57074206 @default.
• W2564262017 hasConcept C71924100 @default.
• W2564262017 hasConcept C85265743 @default.
• W2564262017 hasConcept C86803240 @default.
• W2564262017 hasConcept C95444343 @default.
• W2564262017 hasConcept C98274493 @default.
• W2564262017 hasConceptScore W2564262017C104317684 @default.
• W2564262017 hasConceptScore W2564262017C126322002 @default.
• W2564262017 hasConceptScore W2564262017C137738243 @default.
• W2564262017 hasConceptScore W2564262017C1491633281 @default.
• W2564262017 hasConceptScore W2564262017C167734588 @default.
• W2564262017 hasConceptScore W2564262017C184235292 @default.
• W2564262017 hasConceptScore W2564262017C185592680 @default.
• W2564262017 hasConceptScore W2564262017C203014093 @default.
• W2564262017 hasConceptScore W2564262017C2776694085 @default.
• W2564262017 hasConceptScore W2564262017C2777025900 @default.
• W2564262017 hasConceptScore W2564262017C2777802072 @default.
• W2564262017 hasConceptScore W2564262017C2778749236 @default.
• W2564262017 hasConceptScore W2564262017C2780269544 @default.
• W2564262017 hasConceptScore W2564262017C2781100027 @default.
• W2564262017 hasConceptScore W2564262017C502942594 @default.
• W2564262017 hasConceptScore W2564262017C53227056 @default.
• W2564262017 hasConceptScore W2564262017C55493867 @default.
• W2564262017 hasConceptScore W2564262017C57074206 @default.
• W2564262017 hasConceptScore W2564262017C71924100 @default.
• W2564262017 hasConceptScore W2564262017C85265743 @default.
• W2564262017 hasConceptScore W2564262017C86803240 @default.
• W2564262017 hasConceptScore W2564262017C95444343 @default.
• W2564262017 hasConceptScore W2564262017C98274493 @default.
• W2564262017 hasIssue "10" @default.
• W2564262017 hasLocation W25642620171 @default.
• W2564262017 hasLocation W25642620172 @default.
• W2564262017 hasLocation W25642620173 @default.
• W2564262017 hasLocation W25642620174 @default.
• W2564262017 hasOpenAccess W2564262017 @default.
• W2564262017 hasPrimaryLocation W25642620171 @default.

• next